Beyless Achieves ASPICE CL2 Certification for In-Vehicle System Software Quality
This achievement is particularly meaningful as it demonstrates that the company has secured objective quality reliability by adopting international-standard software development processes from the early development stages, even in an environment that requires rigorous evaluation and verification. In particular, fully covering the design, evaluation, and validation domains within the V-cycle ranging from CL2 SYS 1–5 to SWE 1–6 is the first domestic case in
ASPICE CL2 is an international certification that validates the systematic and consistent execution of the entire software development lifecycle, including development planning, requirements management, design validation, testing, and verification. It has become an essential qualification when collaborating with global OEMs and Tier-1 suppliers.
With this certification, Beyless has met all ASPICE assessment criteria across 15 process areas, including MAN, SYS, SWE, and SUP. This confirms that the company has established a structured and repeatable software development process that goes beyond simple feature implementation. Notably, the CL2 assessment was conducted not through traditional document-based reviews, but through an infrastructure integrated with an Application Lifecycle Management (ALM) system. This validates that Beyless has secured a repeatable and sustainable quality management framework and has reached a level capable of meeting the quality demands of global OEMs.
He added, "The ASPICE CL2 certification showcases Beyless's commitment to quality innovation and compliance with international standards. Moving forward, we will pursue mass-production-level certifications and higher capability levels, including CL3 and beyond, to further strengthen our competitiveness in the global market."
View original content to download multimedia:https://www.prnewswire.com/news-releases/beyless-achieves-aspice-cl2-certification-for-in-vehicle-system-software-quality-302626450.html
SOURCE BEYLESS Co.,Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
- PureHealth Research Utilizes Bioavailable Cranberry and Astragalus in Premium Natural Supplements for Kidney Health
- OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share